2021
Effectiveness of spatially targeted interventions for control of HIV, tuberculosis, leprosy and malaria: a systematic review
Khundi M, Carpenter JR, Nliwasa M, Cohen T, Corbett EL, MacPherson P. Effectiveness of spatially targeted interventions for control of HIV, tuberculosis, leprosy and malaria: a systematic review. BMJ Open 2021, 11: e044715. PMID: 34257091, PMCID: PMC8278879, DOI: 10.1136/bmjopen-2020-044715.Peer-Reviewed Original ResearchConceptsSystematic reviewCommunity public health interventionsGlobal elimination targetsCommunity-based screeningControl of HIVMass drug administrationPublic health interventionsData extraction toolIndoor residual sprayingEvidence of effectWeb of ScienceCochrane DatabaseElimination targetsCommunity screeningInclusion criteriaDrug AdministrationHIVComplex interventionsHealth interventionsInfectious diseasesTuberculosisIntensive interventionIntervention impactMalaria studiesResidual spraying
2020
Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States
Menzies NA, Bellerose M, Testa C, Swartwood N, Malyuta Y, Cohen T, Marks SM, Hill AN, Date AA, Maloney SA, Bowden SE, Grills AW, Salomon JA. Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States. American Journal Of Respiratory And Critical Care Medicine 2020, 202: 1567-1575. PMID: 32645277, PMCID: PMC7706168, DOI: 10.1164/rccm.202003-0526oc.Peer-Reviewed Original ResearchConceptsGlobal TB controlTB incidence trendsEnd TB StrategyTB controlTB casesIncidence trendsEconomic burdenWorld Health Organization's End TB StrategyTB incidence rateGlobal tuberculosis controlHigh-burden countriesTotal economic burdenMajor health benefitsBase case scenarioBirth countryTB incidenceTB epidemiologyTuberculosis controlTB StrategyIncidence rateHealthcare costsIncidence reductionInfection riskTuberculosisSubstantial health
2017
Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study
Verguet S, Riumallo-Herl C, Gomez GB, Menzies NA, Houben RMGJ, Sumner T, Lalli M, White RG, Salomon JA, Cohen T, Foster N, Chatterjee S, Sweeney S, Baena IG, Lönnroth K, Weil DE, Vassall A. Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. The Lancet Global Health 2017, 5: e1123-e1132. PMID: 29025634, PMCID: PMC5640802, DOI: 10.1016/s2214-109x(17)30341-8.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisEnd TB StrategyTuberculosis servicesCatastrophic costsTB StrategyDrug-sensitive tuberculosisCatastrophic financial burdenAnnual household incomeTuberculosis careTuberculosis controlEconomic burdenTuberculosisIntervention effectsMelinda Gates FoundationHousehold incomeIndirect costsFinancial burdenExpansion of accessPatientsTotal annual household incomeTreatmentCareGates FoundationBurdenIntervention scenariosPriority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model
Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLOS Medicine 2017, 14: e1002202. PMID: 28045934, PMCID: PMC5207633, DOI: 10.1371/journal.pmed.1002202.Peer-Reviewed Original ResearchConceptsEase of adherenceTB mortalityTB incidenceNovel drug regimensTB regimenNovel regimenDrug regimensRegimen characteristicsTreatment durationTreatment efficacyRR-TB treatmentTB treatment efficacyRifampicin-resistant TBTB treatment durationDynamic transmission modelTB regimensNew regimensRR-TBTB treatmentMedical contraindicationsPatients' qualitySafety profileBaseline prevalenceTB epidemicTuberculosis treatment
2016
Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models
Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Laurence YV, Qiang S, Siroka A, Sweeney S, Verguet S, Arinaminpathy N, Azman AS, Bendavid E, Chang ST, Cohen T, Denholm JT, Dowdy DW, Eckhoff PA, Goldhaber-Fiebert JD, Handel A, Huynh GH, Lalli M, Lin HH, Mandal S, McBryde ES, Pandey S, Salomon JA, Suen SC, Sumner T, Trauer JM, Wagner BG, Whalen CC, Wu CY, Boccia D, Chadha VK, Charalambous S, Chin DP, Churchyard G, Daniels C, Dewan P, Ditiu L, Eaton JW, Grant AD, Hippner P, Hosseini M, Mametja D, Pretorius C, Pillay Y, Rade K, Sahu S, Wang L, Houben RMGJ, Kimerling ME, White RG, Vassall A. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health 2016, 4: e816-e826. PMID: 27720689, PMCID: PMC5527122, DOI: 10.1016/s2214-109x(16)30265-0.Peer-Reviewed Original ResearchMeSH KeywordsChinaCost-Benefit AnalysisDelivery of Health CareForecastingGoalsHealth Care CostsHealth ExpendituresHealth PolicyHealth ResourcesHealth Services AccessibilityHealth Services Needs and DemandHumansIndiaModels, TheoreticalPatient Acceptance of Health CareQuality-Adjusted Life YearsSouth AfricaTuberculosisConceptsPatient-incurred costsTuberculosis servicesConventional cost-effectiveness thresholdsHigh-burden countriesEnd TB StrategySubstantial health gainsNet cost savingsResource implicationsCost-effectiveness thresholdMost intervention approachesTB StrategyTuberculosis incidenceMost interventionsSocietal perspectiveHealth gainsIntervention mixMelinda Gates FoundationSubstantial healthHealth effectsCurrent practiceExpansion of accessIntervention approachesEmpirical cost dataCost dataInterventionFeasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models
Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, Lin HH, Wu CY, Mandal S, Pandey S, Suen SC, Bendavid E, Azman AS, Dowdy DW, Bacaër N, Rhines AS, Feldman MW, Handel A, Whalen CC, Chang ST, Wagner BG, Eckhoff PA, Trauer JM, Denholm JT, McBryde ES, Cohen T, Salomon JA, Pretorius C, Lalli M, Eaton JW, Boccia D, Hosseini M, Gomez GB, Sahu S, Daniels C, Ditiu L, Chin DP, Wang L, Chadha VK, Rade K, Dewan P, Hippner P, Charalambous S, Grant AD, Churchyard G, Pillay Y, Mametja LD, Kimerling ME, Vassall A, White RG. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health 2016, 4: e806-e815. PMID: 27720688, PMCID: PMC6375908, DOI: 10.1016/s2214-109x(16)30199-1.Peer-Reviewed Original ResearchConceptsEnd TB Strategy targetsPreventive therapyTuberculosis incidenceContinuous isoniazid preventive therapyGlobal tuberculosis targetsIsoniazid preventive therapySymptoms of tuberculosisActive case findingNational Tuberculosis ProgrammeEnd TB StrategyHigh-burden countriesAntiretroviral therapyLatent tuberculosisStrategy targetsTuberculosis burdenTuberculosis careTuberculosis ProgrammeTB StrategyTuberculosis transmissionHealth centersAdditional interventionsTuberculosis interventionsCase findingTuberculosis epidemiologyEpidemiological impact
2013
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibility
2010
Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study
Cohen T, Hedt BL, Pagano M. Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study. BMC Public Health 2010, 10: 355. PMID: 20565947, PMCID: PMC2898828, DOI: 10.1186/1471-2458-10-355.Peer-Reviewed Original Research